Tritrpticin 

Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia^[1][2][3][4].

Tritrpticin (8-64 μg/mL; 16 h) inhibits the growth of E. coli, S. typhimurium, P. aeruginosa, and C. albicans with an MIC of 32 μg/mL, B. subtilis and S. epidermidis with an MIC of 8 μg/mL, and S. aureus with an MIC of 16 μg/mL^[1].
Tritrpticin (100 μg/mL; 1 h) induces 37% hemolysis of human red blood cells at a concentration of 100 μg/mL^[1].
Tritrpticin (8 μg/mL; 2 min) induces 74% Calcein (HY-D0040) leakage from POPC/POPG (3:1) liposomes at a concentration of 8 μg/mL^[1].
Tritrpticin (2.0-16 mg/L; 18 h) exhibits in vitro antibacterial activity against E. coli (MIC 2.0-8.0 mg/L) and E. faecalis (MIC 4-16 mg/L)^[3].
Tritrpticin (10-40 μM; 24 h for Jurkat cells, PBMCs; 4 h for RBCs) potently induces cytotoxicity in Jurkat T-leukemia cells (IC₅₀ = 18.3 μM) and exhibits lower toxicity towards normal PBMCs (IC₅₀ = 40.6 μM) and minimal hemolytic activity against RBCs (IC₅₀ ≥ 65 μM)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tritrpticin (1 mg/kg; i.p.; single dose) produces significant reductions in plasma endotoxin, IL-6, and TNF-α levels in LPS-induced septic shock in Wistar rats^[3].
Tritrpticin (1 mg/kg; i.v.; single dose) reduces 72-hour lethality to 35% and significantly lowers bacterial burdens in multiple tissues and plasma inflammatory mediator levels in cecal ligation and puncture-induced septic shock in Wistar rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1902.25

C₉₆H₁₃₂N₂₈O₁₄

179264-81-4

Val-Arg-Arg-Phe-Pro-Trp-Trp-Trp-Pro-Phe-Leu-Arg-Arg

VRRFPWWWPFLRR

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang ST, et al. Conformation-dependent antibiotic activity of tritrpticin, a cathelicidin-derived antimicrobial peptide. Biochem Biophys Res Commun. 2002;296(5):1044-1050.

  [2]. Infante VV, et al. Effect of the antimicrobial peptide tritrpticin on the in vitro viability and growth of Trichomonas vaginalis. Curr Microbiol. 2011;62(1):301-306.

  [3]. Ghiselli R, et al. The cathelicidin-derived tritrpticin enhances the efficacy of ertapenem in experimental rat models of septic shock. Shock. 2006;26(2):195-200.

  [4]. Arias M, et al. Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. Biochim Biophys Acta Biomembr. 2020;1862(8):183228.